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This study is performed to evaluate the factors associated with the recurrence of myoma
after Myomectomy. Identifying the factors of myoma recurrence will assist the patient and
her gynecologist in deciding the most appropriate method of treatment according to her
specific social, medical and emotional needs. Multiple logistic regression is used to
determine the factors affecting the recurrence. ‘Age of Surgery’, ‘Tumor Size’, ‘Pelvic Pain”
and the interaction between the ‘Age of Surgery’ and ‘Tumor Size’ are significant in the final
model. Kaplan-Meier method is used to calculate the cumulative recurrence rate. The 5 year
cumulative recurrence rate is 24.32% and the 10 year cumulative recurrence rate is 32.57%.
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1

FACTORS AFFECTING RECURRENCE OF
LEIOMYOMA AFTER MYOMECTOMY
Chapter 1
INTRODUCTION
Uterine myomas, more commonly called fibroids, are benign neoplasms of uterine
smooth muscle. They are the most common pelvic tumors in women. In the United States,
uterine myomas are a leading cause of hospitalizations for gynecologyic disorders unrelated
to pregnancy and the most frequent reason for Hysterectomy, accounting for 33% of all such
surgeries annually. In principle, the fibroid tumors can cause infertility, distorting the uterine
cavity or occluding tubes and altering vascularization. Women with these tumors experience
heavy period, menorrhagia, anaemia and pelvic pain. Ultrasound is generally been used to
detect fibroids. It is a painless, safe and reliable way to assess the uterus, ovaries and to look
for uterine fibroids. In this process, sound waves, not radiation, are used to create pictures of
uterus. When the finding fibroids are small and cause no symptoms, no treatment is required.
However, in presence of symptomatic or large fibroids, hysterectomy is the conventional
treatment, which completely removes the uterus. It is recommended for women older than 40
and women younger than 40 who have completed childbearing. Hysterectomy is the only
treatment with the guarantees that there will be no recurrence of fibroids. The drawback is
that after hysterectomy, there is an increased prevalence of problems related to sagging
pelvic organs such as “dropped bladder” (in medical terms these are known as genital
prolapse, such as vaginal vault prolapse, enterocele, cystocele and rectocele). These
conditions may cause symptoms, such as urination and defection disorders, and may require
surgical repair. Also it has been shown that after hysterectomy, women tend to enter
menopause earlier, by as much as four years according to one study. On top of that, as more
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women have become better informed on health issues recent years, they have sought
treatments that preserve the pelvic organs, especially in the presence of a benign disease. In
principle, many women are strongly opposed to the removal of any organs, genital or
otherwise, unless absolutely necessary.
Uterine fibroid embolization (also known as uterine artery embolization) represents a
fundamentally new approach to the treatment of fibroids. Embolization is a minimally
invasive means of blocking the arteries that supply blood to the fibroids. The procedure was
first used in fibroid patients in France as a means of decreasing the blood loss that occurs
during myomectomy. It was discovered that after the embolization, while awaiting surgery,
many patient's symptoms went away and surgery was no longer needed. The blockage of the
blood supply caused degeneration of the fibroids and this resulted in resolution of their
symptoms. This has led to the use of this technique as a stand-alone treatment for
symptomatic fibroids.
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Figure 1: UAE: A tiny particle is injected through blood vessels to block the arteries
supplying fibroids
As of this time, approximately 2000 to 3000 patients have had this procedure worldwide. The expected average reduction in the volume of the fibroids is 50% in three months,
with reduction in the overall uterine volume of about 35%. The long-term outcome is not
known, in that the arteries could reopen or collateral vessels could be recruited which might
allow regrowth of the fibroids. Therefore, it is not yet known if the fibroids can regrow. The
large majority of the patients that had this procedure are finished with childbearing and so
few women have tried to become pregnant after this procedure. Thus far, at least a dozen
patients have become pregnant after this procedure worldwide. As the outcome of pregnancy
following UAE is not known, the procedure is not recommended for women who plan to
have children.
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When the conditions occur as seeking for fertility, Myomectomy is considered. It is a
surgical procedure that allows the gynecologist surgeon to remove the fibroids and preserve
the fertility. There are three methods for Myomectomy: Hysteroscopy, which involves
inserting a lighted viewing instrument through the vagina and into the uterus; Laparoscopy,
which uses a lighted viewing instrument and one or more small cuts (incisions) in the
abdomen; Laparotomy, which uses a larger incision in the abdomen. The method used
depends on the size, location and number of fibroids. Hysteroscopy can be used to remove
fibroids on the inner wall of the uterus that have not grown deep into the uterine wall, such as
intracavitary myomas that are inside the uterus and submucous myomas that are partially in
the cavity and partially in the wall of uteru. Laparoscopy is usually reserved for removing
one or two fibroids, up to about 2 inches across, that are growing on the outside of the uterus,
such as pedunculated myomas. Laparotomy is uses to remove large fibroids, many fibroids at
once or fibroids that have grown deep into the uterine wall.

Figure 2: Types of fibroids are classified by their location.
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Myomectomy requires more expertise and surgical skills than Hysterectomy; it is
more likely to result in prolonged surgery, significant blood loss and other postoperative
complications. Therefore, it is not surprising that the average gynecologist tends to offer
hysterectomy as a treatment for fibroids, rather than Myomectomy.
Myomectomy preserves the fertility for women, however, it has a big drawback: the fibroids
may recur. Clinical studies have reported that the recurrence rates ranging from 5 to 30 %
( Buttram & Reiter 1981) and the most updated paper showed 30% of recurrence rate. This
wide range may be explained by different criteria used in diagnosis and deficiencies in longterm follow-up. The effect of potential prognostic factors has still not been properly
investigated.
Much research has been devoted to finding the factors affecting the recurrence after
Myomectomy. A paper “Recurrence of fibroids after Myomectomy” published in 1991
showed that there were no associations between risk of recurrence and age of the surgery or
number of pregnancy before Myomectomy. It was also said that there was a steady increase
in recurrence-ten years after Myomectomy and fewer recurrences in women who had had a
single fibroid removed. It also gave an explanation for the results: First, pregnancy may have
a long lasting protective effect on the uterus that inhibits the growth of fresh fibroids. Second,
women with small fibroids that have gone undetected at the time of surgery are both less
likely to identifiable fibroids in the future. Third, women who have had one or more
successful pregnancies after Myomectomy are more likely to use combined oral
contraceptives. Another paper from Clinique Universitaire Baudeocque (Paris, France)
published in year 2000 showed that Age, number of tumors are significant factors of
recurrence; the pregnancy after Myomectomy is associated with a lower risk of recurrence
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and it stated that the real risk of recurrence after Myomectomy is difficult to assess. A paper
published in 1991 from several Docrots in Milan, Italy also found out that women gave birth
to a child has a lower rate than those who did not; women with a single fibroid tended to
experience a lower rate and the cumulative 10-year recurrence rate after Myomectomy was
27% and the number of myomas removed at Myomectomy has been associated positively
with the risk of recurrence. In 1998, “Recurrence rate after laparoscopic Myomectomy” was
published and stated that out of 114 patients, the cumulative risk of recurrence rate was
10.6% after 1 year, 31.7% after 3 years and 51.4% after 5 years; risk factors were number of
myomas and depth of penetration.
A retrospective study of factors affecting recurrence after Myomectomy is conducted
of 257 patients underwent Myomectomy from January 1st, 1992 to May 1st, 2007. All
surgeries were done by one surgeon, Dr Hanafi.

Sources of Data
Between 1992 and 2007, 257 women underwent Myomectomy with Dr. Hanafi at Saint
Joseph Hospital. Patients’ surgery information has been collected from their charts and
survey has been conducted through mails, phone calls and personal interview to get the
patients’ pregnancy information after first Myomectomy. Due to the lack of participation of
the survey and consequently censored at the time of their last follow-up visit, plus that the
criteria at least one myoma is larger than 2cm, out of the 257 patients, only 109 patients’
information were fully obtained at the cut off time May 1st 2007.
The patients’ data include BMI, their age at first Myomectomy surgery, number of
pregnancy before the surgey, whether or not have had deliveries before the surgery, number
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of myoma, the largest size of the myoma, willingness of conceive after the surgery,
pregnancy after the surgery, five symptoms before the surgery (heavy period, irregular period,
dysmen, dyspar, pelvic pain) and the response variable Recurrence. The age of those 109
patients is ranged from 23 to 50 and their average age is 36. The BMI is ranged from 16.91 to
56.68 and has an average of 29.5.
Based on Dr. Hanafi 30 years of experience, BMI, willingness of conceive, size of
tumor and the age at first surgery are clinically important. And the paper published before
showed that the number of Myomas is the significant factor. BMI has been discreted into
four groups: Less than 18.5-Light weight; Between 18.5 and 24.9-Normal Weight; Between
25 and 29.9-Overweight; greater than 30-Obesity. Age and tumor size are discreted into three
groups: 20-30; 30-40 and 40-50 for age and 2-4cm; 4-6cm and greater than 6cm. Graph these
three discreted factors associate with their recurrence rate, interesting patterns can be seen.
BMI Group
BMI
Light Weight
<18.5
Normal
18.5-24.9
Over weight 25-29.9
Obesity
>30

N
2
30
31
46

Rec
1
11
8
16

RR
50%
37%
26%
35%

BMI VS RR
55%
50%

RR

45%
40%
35%
30%
25%
20%
<18.5

18.5-24.9

25-29.9

>30

Light Weight

Normal

Over weight

Obesity

Table1: BMI versus Recurrence Rate

8

From the table1, it is surprising that the heavier the weight the lower the rate of
recurrence. And the lowest recurrence rate occurred at the Over weight group, which is 26%.

Age Group
20-30
30-40
40-50

N
9
77
23

Rec
3
30
3

RR
33%
39%
13%

Age VS RR
40%
35%
RR

30%
25%
20%
15%
10%
20-30

30-40

40-50

Age

Table2: Age Groups versus BMI

The table 2 has shown increasing rate from 20-30 to 30-40 and decreasing rate from
30-40 to 40-50. However, for the age group of 20-30, there are only 9 observations.

Size Group
2-4 cm
4-6 cm
6+ cm

N
59
27
23

Rec
24
8
4

RR
41%
30%
17%
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Tumor Size VS RR
45%
40%
RR

35%
30%
25%
20%
15%
2-4 cm

4-6 cm

6+ cm

Size

Table 3: Tumor Size versus Recurrence Rate

Table 3 has shown a linear relationship between the tumor size and the rate of
recurrence. This indicates that as the tumor size gets larger, the rate of recurrence gets lower.

Pregnancy Before VS RR
34%

RR

33%

32%

31%
Yes

No
Pregnancy

Table 4: Pregnancy Before versus Recurrence Rate
Table 4 has shown that whether the patients have pregnancy before the first surgery
does not make much difference. The recurrence rate for pregnancy before is 33% compare
with non-pregnancy 32%.
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A classification table is made for the factor willingness of conceive.
Full Records On Patients
109
Desire Pregnancy
65

←

→ NO Desire Pregnancy
44

↓
←→
Pregnancy
8

Recurrence:

↓
← →

No Pregnancy
57

Pregnancy
5

No Pregnancy
39

↓

↓

↓

↓

3

22

3
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With patients who desire pregnancy, the recurrence rate is 37.5% for those patients
actually got pregnancy and 38.6% who did not get pregnancy. And among those patients who
do not desire pregnancy, the recurrence rate is 60% for those who became pregnancy and
20.5% who did not get pregnancy. And there were 38.5% of patients who desire to conceive
had a recurrence and only 25% of those who did not desire to conceive experienced
recurrence.
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Chapter 2
METHODOLOGY
Method of Analysis
The data of patients’ consists primarily of dichotomous variables. Variables such as
Pregnancy-before, willingness-to-conceive, whether or not having any symptoms, the
response variable-recurrence is also a binary variable. Many different methods are available
to analyze this data; however, for this study multiple logistic regression has been chosen as
an optimal method to use for the dichotomous variables. The goal of the method is to select
those variables that result in a best model to predict the factors that affecting the recurrence
of Myomectomy.

Statistical Analysis

A univariate analysis was conducted on each of the independent variables to determine
which variables were significant in predicting the recurrence after Myomectomy. Variables
whose univariate test has a P-value < 0.25 is a candidate for the model along with all
variables of known clinical importance. The 0.25 level is suggested to be used as a screening
criterion for variable selection is based on work by Bendel and Afifi( 1977) on linear
regression and on the work by Mickey and Greenland (1989) on logistic regression.
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Label
BMI
Age of Surgery
Pregnancy Before
Delivery
Number of Myoma
Tumor Size
Single Tumor
Willing To Conceive
Pregnancy After Surgery
Heavy Period
Irregular Period
Dyspar
Dysmen
Pelvic Pain

Test
Likelihood Ratio
Likelihood Ratio
Likelihood Ratio
Likelihood Ratio
Likelihood Ratio
Likelihood Ratio
Likelihood Ratio
Likelihood Ratio
Likelihood Ratio
Likelihood Ratio
Likelihood Ratio
Likelihood Ratio
Likelihood Ratio
Likelihood Ratio

Chi-Square
0.0012
5.1041
0.9364
0.0591
0.0027
7.3906
0.0007
2.1917
1.1
0.3278
0.2353
0.002
1.3333
1.0118

DF
1
1
1
1
1
1
1
1
1
1
1
1
1
1

P> Chi-Square
0.9726
0.0239
0.3332
0.8079
0.9585
0.0066
0.9784
0.1388
0.2943
0.5669
0.6276
0.9643
0.2482
0.3145

Table 5: Results from Univariate Test.
Another method to variable selection is to use a stepwise method in which variables
are selected from the model in a sequential fashion based solely on statistical criteria.
Stepwise selection of variables is widely used in linear regression. All major software
packages have either a separate program or an option to perform this type of analysis for the
logistic regression.

Analysis of Maximum Likelihood Estimates
Parameter
Intercept
Age of surgery
Tumor Size
Willing to conceive
Dysme
Pelvic Pain

DF

Estimate

1
1
1
1
1
1

3.5732
-0.1046
-0.3734
0.7306
0.6641
1.1277

Standard Wald ChiError
Square
2.0102
3.1596
0.0494
4.4799
0.1323
7.9728
0.4924
2.202
0.4877
1.8542
0.5696
3.9206

Table 6: Results from stepwise selection with SLE=0.4, SLS=0.3.

Pr> ChiSquare
0.0755
0.0343
0.0047
0.1378
0.1733
0.0477
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Table 5 and Table 6 showed that Age of surgery, tumor size and pelvic pain are
potentially significant.

Variable Transformation
Once a model that contains the essential variables has been established, the assumption
of linearity in the logit should be checked. Two methods to assess this problem: Design
variables and fractional polynomials. A design variable uses a scatter plot smooth, plotting
the results on the logit scale. Unfortunately, scatter plot smoothing methods are not easily
extended to multivariable models and thus have limited applicability in the model refinement
step. Another more analytic approach is to use the method of fractional polynomials,
developed by Royston and Altman (1994) to do transformation. We wish to determine what
value of x p yields the best model for the covariate. Royston and Altman propose replacing
full maximum likelihood estimation of power by a search through a small but reasonable set
of possible values. For a single continuous covariate, the logit, which is linear in the
covariate is
g ( x, β ) = β 0 + xβ 1
Where β denotes the vector of model coefficients. One way to generalize this function is to
specify it as
J

g ( x, β ) = β 0 + ∑ F j ( x ) β j
j =1

The functions F j ( x) = x P1 are a particular type of power function. The value of the

first function is F1 ( x) = x P1 . In theory, the power P1, could be any number, but in most
applied settings it makes sense to try to use something simple. Royston and Altman (1994)
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propose restricting the power to be among those in the set ϑ = (-2,-1,-0.5, 0, 0.5, 1, 2, 3).
Where P1=0 denotes the log of the variable. The remaining functions are defined as
 x p j , p j ≠ p j −1
F j ( x) = 
 F j −1 ( x) ln( x), p j = p j −1
for j=2…J and restricting powers to those in ϑ .
Implementation of the method requires, for J=1, fitting 8 models that is P1< ϑ . The best
model is the one with the largest log likelihood. The process is repeated with J=2 by fitting
the 36 models obtained from the distinct pairs of powers, that is, ( p1, p 2 ) ∈ ϑ × ϑ and the
best model is again the one with the largest log likelihood.
The relevant question is whether either of the two best models is significantly better
than the linear model. Let L(1) denote the log likelihood for the linear model, J=1, and P1=1,
and L(P1) denote the log likelihood for the best J=1 model and L(P1,P2) denote the log
likelihood for the best J=2 model. Then compare the partially likelihood ratio test with the
linear model to the best J=1 model, is approximately distributed as chi-square with 1 degree
of freedom under the null hypothesis of linearity in x. The partial likelihood ratio test
comparing the best J=1 model to the best J=2 model is approximately distributed as chisquare with 2 degrees of freedom. Similarly, the partial likelihood ratio test comparing the
linear model to the best J=2 model is distributed approximately as chi-square with 3 degrees
of freedom.
‘Age of surgery’ and ‘Tumor size’ are the continuous variables in the model that need to
be checked for linearity.
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Transformation Models

-2 Log L

Best J=2 model:

Age = x 3 + x 3 ∗ ln ( x )

Best J=1 model:

Age

= x

3

130.0698
131.9099

Linear model:

133.189
Partially Likelihood Test

DF
1
2
3

G (1, p1 )

G [ p1, ( p1, p 2 )]

G [1, ( p 1, p 2 )]

Chi-Sqare

P>Chi-Square

1.2791

0.2580

1.8401

0.3984

3.1192

0.3736

Table 7: Variable ‘Age of Surgery’ Transformation

Age transformation table has shown the best J=1 model, best J=2 model and the
comparisons with the linear model. However, the transformation models are not significantly
different than the linear model; therefore, linear model is selected. Same process for the
variable ‘Tumor size’, and the linear model is selected too.

Interaction

Interaction effects are an important consideration for any model and must be
thoroughly explored to determine if there is a significant interaction that should be included
in the final model. In any model an interaction between two variables implies that the effect
of one of the variables is not the same over levels of the each other. The final decision as to
whether an interaction term should be included in a model should be based on statistical as
well as practical considerations. The correlation for each of the variable is calculated to
assess the significant interaction.
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Recurrence

BMI

Age of
Surgery

Pregnancy
Before
Delivery

Recurrence

1.00

BMI
Age of
Surgery

0.00

1.00

-0.21

0.11

1.00

Pregnancy
Before

Number of Tumor Single
Myoma
Size
Tumor

0.09

-0.03

0.19

1.00

Delivery
Number of
Myoma

-0.02

0.07

0.19

0.64

0.00

-0.01

0.00

-0.23

-0.31

1.00

Tumor Size

-0.24

0.00

-0.08

-0.13

-0.06

0.17

1.00

Single Tumor
Willing To
Conceive

0.00

-0.13

0.02

0.20

0.14

-0.62

0.02

1.00

Willing To
Conceive

Pregnancy
After

Heavy
Period

Irregular
Period
Dyspar Dysmen

1.00

0.14

-0.05

-0.16

0.14

-0.02

0.05

-0.04

0.06

1.00

Pregnancy
After

0.10

-0.23

-0.11

-0.01

-0.17

0.03

-0.01

0.02

0.01

1.00

0.13

0.09

-0.19

-0.02

0.03

0.04

-0.04

-0.21

-0.22

1.00

Heavy Period

-0.06

Irregular
Period

0.05

0.05

0.00

-0.08

0.00

0.05

-0.02

-0.03

0.07

-0.12

0.06

1.00

Dyspar

0.00

-0.03

-0.17

0.01

0.08

0.00

0.04

-0.09

-0.11

-0.12

0.24

-0.21

1.00

Dysmen
Pelvic Pain

0.11
0.10

-0.02
-0.09

-0.19
0.06

-0.19
0.06

-0.11
-0.06

-0.01
-0.07

-0.01
0.16

-0.02
0.17

-0.17
-0.01

-0.09
0.01

0.23
0.12

-0.08
-0.02

0.37
-0.11

1.00
-0.23

Table 8: Correlation of the variables
The correlations among variables indicate the possible multicollinearity problem. The
final model should be carefully examined and the interpretation also should be done with
caution. A stepwise logistic regression with all the main variables and the interactions is
conducted to determine whether any of those interactions are significant with SLE=0.15 and
SLS=0.15. Only the interaction between Age of surgery and Tumor size turn out to be
significant in the model.
Analysis of Maximum Likelihood Estimates
Parameter
Intercept
Age of Surgery
Tumor Size
Pelvic Pain
Age * Tumor size

DF

Estimate

1
1
1
1
1

11.6422
-0.3102
-1.8179
0.9076
0.0412

Table 9: Final Model of Logistic Regression

Standard
Error
4.9733
0.1375
0.9624
0.5326
0.0264

Wald ChiSquare
5.4802
5.0905
3.5683
2.9036
2.4401

Pr> ChiSquare
0.0192
0.0241
0.0589
0.0884
0.1183
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Based on the results of the variable selection process, a final model has been developed
to determine the risk factors associated with recurrence of fibroids. The final logistic
regression model is:

πˆ ( x ) =

e11.6422− 0.3102* Age −1.8179*Tumorsize + 0.9076* pelvicpain+ 0.04128* Age*Tumorsize
1 + e11.6422− 0.3102* Age−1.8179*Tumorsize + 0.9076* pelvicpain+ 0.04128* Age*Tumorsize
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Goodness of Fit

Once the model is established, it is important to determine if the model is a good fit of
the data. Also, we need to know if the model is a good predictor for the response variable.
Finally, we like to check if the overall patterns of the model are relevant in representing the
predicted outcomes. Hosmer Lemeshow(HL) goodness-of-fit can be used for some of the
above purposes. The null hypothesis being tested with HL test is that the model is a good fit.
HL divided the data into g=10 deciles of risk groups to do the comparisons between the
observed to the expected number of outcomes for value of x. The first group containing the
n1prime=n/10 subjects having the smallest estimated probabilities, and the last group
containing the n10prime=n/10 subjects having the largest estimated probabilities. The HL
test uses a Pearson Chi-Square statistic
g
(Ok − nk' π k ) 2
ˆ
C=∑ '
k =1 n k π k (1 − π k )

Where n k' is the total number of subjects in the K th group, C k denotes the number of
covariate patterns in the K th decile,
Ck

Ok = ∑ y i
j =1

is the number of response among the C k covariate patterns, and
Ck

m j πˆ j

j =1

nk'

πk = ∑

is the average estimated probability.
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The distribution of Ĉ was determined by simulation studies to be approximately

χ 2 with 8 degrees of freedom (Hosmer and Lemeshow, 1980). The HL test rejects the fit of
logistic model at α level when C 〉 χ 82 ,1−α .

Partition for the Hosmer and Lemeshow Test

Group

Total

1
2
3
4
5
6
7
8
9
10

11
11
11
11
11
11
11
11
11
10

Recurrence = 1
Observed Expected
0
0.69
2
1.44
1
1.93
3
2.54
4
3.06
4
3.69
4
4.32
6
5.43
6
5.85
6
7.06

Recurrence = 0
Observed
Expected
11
10.31
9
9.56
10
9.07
8
8.46
7
7.94
7
7.31
7
6.68
5
5.57
5
5.15
4
2.94

Hosmer and Lemeshow Goodness-Of-Fit Test
Chi-Square
2.7828

DF
8

Pr>Chisq
0.9472

Table 10: HL Goodness fit test
The large P-value from Table proved that the model is a good fit of the data.

ROC

Sensitivity and specificity are two diagnostic measurements used to assess the model
in terms of reliability the model to classify observations correctly. Sensitivity is the
probability of correct classification among all true positives. On the other hand, the
specificity is the probability of correct classification among all true negatives. Sensitivity and
Specificity rely on a single cut point to classify a test results as positive. The most commonly
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used measurement to gauge the classification method is the area under the ROC curve
(Receiver operating Characteristic), which is a plot of sensitivity versus 1-specificity overall
possible cut points. This curve, ranges from zero to one, provided a measure of the model’s
ability to discriminate between those subjects who experience the outcome of interest versus
those who don’t. If the objective was to choose an optimal cut point for purpose of
classification, one might select a cut point that maximizes one of sensitivity and specificity,
while fixed the other one. The other way to gauge the discrimination power is to find the
point, where sensitivity equals to the specificity. For example, if the cutoff point yield
sensitivity =specificity=0.9, then the method is very good.

Prob
Level
5%
10%
15%
20%
25%
30%
35%
40%
45%
50%
55%
60%

Correct Identifies

Incorrect Identifies

Recur=1 Recur=0 Recur=1
36
7
66
34
12
61
32
21
52
30
31
42
28
36
37
25
41
32
23
52
21
20
56
17
16
57
16
11
61
12
8
64
9
7
66
7

Recur=0
0
2
4
6
8
11
13
16
20
25
28
29

Sensitivity Specificity
100
94.4
88.9
83.3
77.8
69.4
63.9
55.6
44.4
30.6
22.2
19.4

9.6
16.4
28.8
42.5
49.3
56.2
71.2
76.7
78.1
83.6
87.7
90.4

Table 11: Sensitivity and Specificity with different probability Level

False
False
Positive Negative
64.7
64.2
61.9
58.3
56.9
56.1
47.7
45.9
50
52.2
52.9
50

0
14.3
16
16.2
18.2
21.2
20
22.2
26
29.1
30.4
30.5
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Figure 3: Sensitivity and Specificity

Figure 4: ROC Curve
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As a general rule,
If ROC=0.5: this suggests no discrimination
If 0.7< ROC< 0.8, this is considered acceptable discrimination
If 0.8< ROC< 0.9, this is considered excellence discrimination
If ROC> 0.9, this is considered outstanding discrimination.

Association of Predicted Probabilities and Observed Responses
Percent Concordant
Percent Disconcordant
Percent Tied
Pairs

73.4
26.3
0.3
2628

Somers' D
Gamma
Tau-a
C

0.471
0.473
0.21
0.736

Table 12: ROC Value
The Area under the curve is 0.736, which is considered acceptable discrimination.
Cross Validation

Five fold Cross-Validation is used to examine the accuracy of the ROC found in the
final model. The original 109 patients’ data has been partitioning into five sub-data. Of the
five sub-data, a single sub-data is retained as the validation data for testing the model, and the
remaining four are used as training data. The same main effects and interactions terms used
to find the final model are adopted here for the training data. A new model is created and
substituted into the retained testing data. A final ROC value is calculated for this testing data.
The cross-validation process repeated five times with each of those sub-data used exactly
once as testing data. The five ROC results are averaged and compare with the final model in
order to calculate the shrinkage. Randomization plays an important role in this cross-
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validation procedure. The original data is randomly assigned to those five sub-data. Proc Plan
is used in SAS to accommodate this process.
Training Data

Average
Shrinkage

Subdata

0.814
0.718
0.735
0.667
0.747
0.688
0.766
0.556
0.75
0.726
0.7624
0.671
0.7624-0.671=0.0914

Table 13: Example of Cross Validation
Repeat the process five times; the average shrinkage of AUC is 0.12.
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Survival Analysis

Survival analysis has been conducted in order to find out the cumulative proportion of
the patients who did not have the recurrence of fibroids. The Kaplan-Meier estimator (also
known as product limit estimator) is used. It estimates the survival function for life-time data.
In medical research, it might be used to measure the fraction of patients living for a certain
amount of time after surgery. An economist might measure the length of time people remain
unemployed after a job loss. An engineer might measure the time until failure of machine
parts.
An important advantage of the Kaplan-Meier curve is that the method can take into
account "censored" data — losses from the sample before the final outcome is observed (for
instance, if a patient withdraws from a study). On the plot, small vertical tick-marks indicate
losses, where patient data has been censored. When no truncation or censoring occurs, the
Kaplan-Meier curve is equivalent to the empirical distribution.
A plot of the Kaplan-Meier estimate of the survival function is a series of horizontal
steps of declining magnitude which, when a large enough sample is taken, approaches the
true survival function for that population. The value of the survival function between
successive distinct sampled observations is assumed to be constant.
Let S(t) be the probability that an item from a given population will have a lifetime
exceeding t. For a sample from this population of size N let the observed times until death of
N sample members be
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Corresponding to each ti is ni, the number "at risk" just prior to time ti, and di, the number of
deaths at time ti.
The nonparametric maximum likelihood estimate of S(t) is
Ŝ (t ) = ∏
ti 〈 t

ni − d i
ni

When there is no censoring, ni is just the number of survivors just prior to time ti. With
censoring, ni is the number of survivors less the number of losses (censored cases). It is only
those surviving cases that are still being observed (have not yet been censored) that are "at
risk" of an (observed) death

Figure 5: Kaplan-Meier Cumulative Recurrence Rate
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Figure 6: Kaplan-Meier Survival Rate

Figure 6 shows the survival curve. It seems that the recurrence rate is much higher for
the first 4 years comparing with the next 10 years. This could be an important information for
medical doctors who give advises to patients.
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Chapter 3
RESULTS
Odds Ratio

After check the goodness fit of the model, the consideration of the interpretation of
logistic regression coefficients can be made, especially with the independent variable is
dichotomous. Odds ratio is a measure of impacts of independent variables which has been
widely used, especially in medical field. The odds are a way representing probabilities, it
approximates how much more likely (or unlikely) it is for the outcome to be present among
those levels of dichotomous variables. In the study, ‘Pelvic pain’ is a dichotomous variable
and it is significant in the final model. The odds ratio for ‘Pelvic pain’ is 2.478, and the 95%
confidence interval is (0.873, 7.40). The interpretation of this could be that the patients who
experience the symptom ‘Pelvic pain’ are approximately 2.5 times of having recurrence to
those patients who don’t experience the symptoms. However, the confidence interval
contains one, the odds ration 2.5 may not be that significant.
From the survival study, the 5 year cumulative recurrence rate is 24.32% and the 10
year cumulative recurrence rate is 32.57%. Factors are significant in the final model are ‘Age
of surgery’, ‘Tumor size’, ‘Pelvic pain’ and the interaction between the ‘Age of surgery’ and
‘Tumor size’.
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Chapter 4
DISCUSSION

The result from the cross validation has a very big shrinkage in average and this may be
caused by the small sized dataset. Partial Least Square method might be an option of this
Logistic regression model and will be conducted in a future study.
A patient with symptomatic uterine myoma wants to know the chances of recurrence of
myoma after Myomectomy and the factors that may affect recurrence if she chooses this
surgery as her treatment option. Recent literature reviews have suggested that the variation in
length of follow-up and criteria for recurrence make it difficult to compare the results of
previous studies.
Recurrence of myoma after Myomectomy has been reported based on diagnosis by palpation,
by systematic transvaginal ultrasonography, or by the need for a second surgery. The current
study used transvaginal ultrasonography to diagnose recurrence, counting only tumors that
were at least 2cm in diameter. The crude recurrence rate used in other studies represents the
minimum myoma recurrence rate and will underestimate the true recurrence rate, which was
calculated by method of Kaplan-Meier.
This risk should not rule out the use of Myomctomy. The recurrence occurs after quite
a long time after the surgery; patients could use this time to have children. The risk of
recurrence is linked with the persistence of small nuclei within the myometrium, which are
undetectable during the operation. It would be an advantage to know what the growth factors
are, and how to use those factors to identify groups at high risk of recurrence who could then
benefit from more suitable treatment strategies or drug treatment to prevent recurrence.
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SAS CODE
*************Rename*******************;
data lu.finaldata2;
set lu.finaldatafull;
rename ID=Var1
recurrence=Y
height=var2
weight=var3
BMI=var4
age_1st_myo=var5
preg_before=var6
delivery=var7
number_of_leiomyoma=var8
tumor_size=var9
single_tumor=var10
willing_to_conceive=var11
pregnancy_after_myomectomy=var12
heavy=Var13
irregular=Var14
dyspar=Var15
dysmen=var16
pelvic_pain=var17
;
run;
**************Discretize age, tumor-size , number of tumor, BMI*********;
data lu.discretedata;
set lu.finaldata;
if Age_1st_myo < 30 then Agegroup1=1; else Agegroup1=0;
if Age_1st_myo > 30 and Age_1st_myo < 40 then Agegroup2=1; else
Agegroup2=0;
if BMI < 24.9 then BMIgroup1=1; else bmigroup1=0;
if BMI > 24.9 and BMI < 29.9 then BMIgroup2=1; else bmigroup2=0;
if BMI > 30 then BMIgroup3=1; else bmigroup3=0;
if tumor_size > 1.9 and tumor_size < 4 then sizegroup1=1; else
sizegroup1=0;
if tumor_size > 4 and tumor_size < 6 then sizegroup2=1; else sizegroup2=0;
if number_of_leiomyoma < 4.1 then numbergroup=1; else numbergroup=0;
run;
********logistic regression model**********;
Proc logistic data=lu.finaldata2 descending ;
model y=var4-var17/selection=stepwise sle=0.4 sls=0.3 lackfit;
run;
Univariate Analysis;
%macro logitreg(label,tvarlist);
ODS OUTPUT Logistic.GlobalTests=testout;
proc logistic descending data=lu.myoma2;
model y= &tvarlist;
run;
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data one;
label="&label";
run;
data testout;
merge one testout(obs=1);
run;
data report;
set report testout;
run;
%mend;
%logitreg(var4,var4);
********Run var2 first!!!!********;
Data total;
Set testout;
Run;
%macro lu ;
%do i=3 %to 17;
%logitreg (var&I, var&i);
Data total;
Set total testout;
Run;
%end;
%mend;
%lu;
*********correlations*************************;
proc corr data=lu.finaldata outp=lu.Corr noprint;
var recurrence BMI age_1st_myo preg_before delivery number_of_leiomyoma
tumor_size single_tumor
willing_to_conceive pregnancy_after_myomectomy heavy irregular dyspar
dysmen pelvic_pain;
run;
********************* Included interaction with BMI, PB***********;
Proc logistic data=lu.finaldata2 descending ;
model y=var4-var17 var5*var9 var5*var17 var9*var17 var4*var5 var4*var9
var4*var17 var6*var5 var6*var9 var6*var17
var8*var5 var8*var9 var8*var17/selection=stepwise sle=0.3 sls=0.2;
run;
*************Variable Transformation****************;
data one;
set lu.finaldata1;
p1=-2;p2=-1;p3=-0.5;p4=0;p5=0.5;p6=1;p7=2;p8=3;
run;
%macro fractional(var);
data out1factor out2factor;
if 1=1 then delete;
run;
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%do n=1 %to 8;
data sample&n;
set one;
if &var=0 then u1=0;
else do;
if p&n=0 then u1=log(&var);else u1=&var**p&n;
end;
run;
proc logistic descending data=sample&n outest=out&n;
model y=u1;
run;
data out&n;
merge out&n one(obs=1);
f1=p&n;D=-2*_lnlike_;
keep f1 D;
run;
data out1factor;
set out1factor out&n;
run;
%do m=1 %to 8;
data sample&n&m;
set one;
/* if p&n=0 then u1=log(var65);else u1=var65**p&n;
if p&m=p&n then u2=log(var65)*u1;else if p&m=0 then
u2=log(var65);else u2=var65**p&m;*/
if &var=0 then u1=0;
else do;
if p&n=0 then u1=log(&var);else u1=&var**p&n;
end;
if &var^=0 then do;
if p&m=p&n then u2=log(&var)*u1;
else if p&m=0 then u2=log(&var);else u2=&var**p&m;
end;
else u2=0;
run;
proc logistic descending data=sample&n&m outest=out&n&m;
model y=u1 u2;
run;
data out&n&m;
merge out&n&m one(obs=1);
f1=p&n;f2=p&m;D=-2*_lnlike_;
keep f1 f2 D;
run;
data out2factor;
set out2factor out&n&m;
run;
%end;
%end;
%mend fractional;
%fractional(var11);
proc iml;
use out1factor;
read all var{f1 D} into model1;
close out1factor;
L1=model1[1,2]; P1=model1[1,1];
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nrow1=nrow(model1);
do i=2 to nrow1;
if model1[i,1]=1 then L=model1[i,2];
if model1[i,2]<L1 then do;
L1=model1[i,2];P1=model1[i,1];
end;
end;
use out2factor;
read all var{f1 f2 D} into model2;
close out2factor;
L2=model2[1,3]; P21=model2[1,1];P22=model2[1,2];
nrow2=nrow(model2);
do i=2 to nrow2;
if model2[i,3]<L2 then do;
L2=model2[i,3];P21=model2[i,1];P22=model2[i,2];
end;
end;
if L-L1>3.84 then do; /*chi-sq(.95,1)=3.84; chi-sq(.95,2)=5.99;
chi-sq(.95,3)=7.81;*/
if L1-L2>5.99 then print 'the best is model2 with power'
P21 'and' P22;
else print 'the best is model1 with power' P1;
end;
else do;
if L-L2>7.81 then print 'the best is model2 with power' P21
'and' P22;
else print 'the best is linear model' ;
end;
quit;
***********CROSS VALIDATION*************************;
data a;
set lu.myoma2(keep=var1);run;
proc plan seed=30000;
factors var1=109;
output data=a out=b;
run;
data b;
set b;
seq=_n_;
if seq<=22 then group=1;
else if seq>22 and seq<=44 then group=2;
else if seq>44 and seq<=66 then group=3;
else if seq>66 and seq<=88 then group=4;
else group=5;
run;
proc sort data=b;by var1;run;
data lu.trial6;
merge lu.myoma2 b;
by var1;
run;
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proc sort data=lu.trial6;
by group;run;
data group1 group2 group3 group4 group5;
set lu.trial6;
if group=1 then output group1;
else if group=2 then output group2;
else if group=3 then output group3;
else if group=4 then output group4;
else output group5;
run;
data group1234;
set group1 group2 group3 group4;
run;
data group1235;
set group1 group2 group3 group5;
run;
data group1245;
set group1 group2 group4 group5;
run;
data group1345;
set group1 group3 group4 group5;
run;
data group2345;
set group2 group3 group4 group5;
run;
*** For Group 5***;
Proc logistic data=group1234 descending ;
model y=var4-var17 var5*var9 var5*var17 var9*var17 var4*var5 var4*var9
var4*var17 var6*var5 var6*var9 var6*var17
var8*var5 var8*var9 var8*var17/selection=stepwise sle=0.15 sls=0.15;
run;
data group5m;
set group5;
A=-0.1665*var5-0.4706*var9+0.8982*var17;
run;
proc logistic data=group5m descending;
model y=A;
run;
********for group4******;
proc logistic data=group1235 desc;
model y=var4-var17 var5*var9 var5*var17 var9*var17 var4*var5 var4*var9
var4*var17 var6*var5 var6*var9 var6*var17
var8*var5 var8*var9 var8*var17/selection=stepwise sle=0.15 sls=0.15;
run;
data group4m;
set group4;
A=-0.0921*var5-0.2866*var9;
run;
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proc logistic data=group4m descending;
model y=A;
run;
********For group 3*******;
proc logistic data=group1245 desc;
model y=var4-var17 var5*var9 var5*var17 var9*var17 var4*var5 var4*var9
var4*var17 var6*var5 var6*var9 var6*var17
var8*var5 var8*var9 var8*var17/selection=stepwise sle=0.15 sls=0.15;
run;
data group3m;
set group3;
A=-0.1526*var5-0.4979*var9+0.9995*var16+1.8035*var17;
run;
proc logistic data=group3m descending;
model y=A;
run;
*******For group 2*******;
proc logistic data=group1345 desc;
model y=var4-var17 var5*var9 var5*var17 var9*var17 var4*var5 var4*var9
var4*var17 var6*var5 var6*var9 var6*var17
var8*var5 var8*var9 var8*var17/selection=stepwise sle=0.15 sls=0.15;
run;
data group2m;
set group2;
A=-0.3335*var5-1.899*var9+0.2402*var6+0.0464*var5*var9;
run;
proc logistic data=group2m descending;
model y=A;
run;
******For group 1*******;
proc logistic data=group2345 desc;
model y=var4-var17 var5*var9 var5*var17 var9*var17 var4*var5 var4*var9
var4*var17 var6*var5 var6*var9 var6*var17
var8*var5 var8*var9 var8*var17/selection=stepwise sle=0.15 sls=0.15;
run;
data group1m;
set group1;
A=-0.3798*var5-2.4964*var9+1.0510*var11+5.6351*var17+0.0644*var5*var91.0496*var9*var17;
run;
proc logistic data=group1m descending;
model y=A;
run;
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**********************ROC************************;
Ods listing close;
ODS output Logistic.Classification=classification;
Proc logistic data=lu.myoma2 descending ;
model y=var4-var17 var5*var9 var5*var17 var9*var17 var4*var5 var4*var9
var4*var17 var6*var5 var6*var9 var6*var17
var8*var5 var8*var9 var8*var17/selection=stepwise sle=0.15 sls=0.15 ctable
outroc=fit details pprob= (0.05 to 0.6 by 0.05);
run;
ods trace off;
data fit1;
set fit;
if _step_^=6 then delete;
run;
proc gplot data=fit1;
plot _sensit_*_1mspec_;
run;
ODS listing close;
ODS output Logistic.parameterestimates=logisticmodelinfo;
Proc logistic data=lu.myoma2 descending ;
model y=var4-var17 var5*var9 var5*var17 var9*var17 var4*var5 var4*var9
var4*var17 var6*var5 var6*var9 var6*var17
var8*var5 var8*var9 var8*var17/selection=stepwise sle=0.15 sls=0.15;
run;
data roc3;
set roc1;
if _step_^=6 then delete;
run;
data roc2;
set roc3;
spec=1-_1mspec_;
run;
symbol1 i=join v=none;
proc gplot data=roc2;
plot _sensit_*_prob_=1 spec*_prob_=1 / overlay haxis=0 to 1 by 0.25
vaxis=0 to 1 by 0.1;
run;

**********SURVIVAL********;
data lu.survival1;
set lu.survival;
Duraition=INTCK('month',first_surgery_date,date);
run;
data lu.kaplan1;
set lu.kaplan;
retain stemp 1;
stemp=stemp*(1-recurrence/atrisk);
survival=stemp;
CRR=1-stemp;
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run;
goptions reset=global
rotate=landscape
gunit=pct
htext=2.5
ftext=centb
gsfmode=replace
device=pscolor
gaccess=gsasfile;
symbol1 color=blue i=step1j line=1 w=3;
axis1 label=(a=90 h=2 c=black"Survival") order=(0.4 to 1 by 0.1);
axis2 label=(h=2 c=black"Months") order=(0 to 190 by 10);
proc gplot data=lu.kaplan1;
plot survival*duration/vaxis=axis1 haxis=axis2;
run;
***********************************************;

